May 20 2026 MHRA approves Krystal’s Vyjuvek
The Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the use of B-Vec (Vyjuvek) developed by Krystal Biotech Inc., for the treatment of Dystrophic Epidermolysis Bullosa in patients from birth onwards.
B-Vec is a topical gene therapy gel which can be applied to wounds. The MHRA approval authorises use from birth onwards.
``This approval provides a new treatment option for patients living with dystrophic epidermolysis bullosa, a rare genetic condition that can cause fragile skin and recurrent wounds. “As with all medicines, we will continue to closely monitor the safety and effectiveness of beremagene geperpavec as it is used more widely.``
B-Vec was approved by the FDA in 2023, and approved by the European Commission in 2025 (although pricing and reimbursement decisions are taken at individual member state level).
In the UK, the MHRA is the first step to the treatment becoming available on the NHS. The next step is approval by NICE – the National Institute for Health Care Excellence – who meet this week (21st May). Cure EB and patients have supported the process by providing case studies of living with DEB, the lack of effective treatments for DEB, as well as lived experience of using B-Vec from patients with access to the treatment in the US and Europe. Sohana Collins, the reason we started Cure EB, and Natasha Hersham, mum to Abe who has RDEB and has been using B-Vec, will be attending the committee meeting as a Cure EB nominated patient experts.